Neo Ivy Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Neo Ivy Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,256	Closed	-$2.84M	–	540
2025 Q3	$2.84M	Buy	+7,256	New	+$3.03M	0.69%	36
2022 Q4	$539K	Buy	+1,866	New	+$569K	0.36%	114
2022 Q3	–	Sell	-318	Closed	-$89K	–	571
2022 Q2	$89K	Buy	318 +198	+165%	+$53K	0.24%	159
2022 Q1	$32K	Buy	+120	New	+$28.5K	0.03%	408
2021 Q4	–	Sell	-906	Closed	-$263K	–	644
2021 Q3	$263K	Buy	906 +131	+17%	+$25.6K	0.3%	123
2021 Q2	$156K	Buy	775 +713	+1,150%	+$149K	0.16%	213
2021 Q1	$13K	Buy	+62	New	+$13.6K	0.01%	419
2020 Q3	–	Sell	-906	Closed	-$263K	–	633
2020 Q2	$263K	Buy	+906	New	+$246K	0.3%	123
2020 Q1	–	Sell	-3,064	Closed	-$671K	–	555
2019 Q4	$671K	Sell	3,064 -4,080	-57%	-$826K	0.78%	55
2019 Q3	$1.29M	Buy	+7,144	New	+$1.26M	0.84%	4
2019 Q2	–	Sell	-1,318	Closed	-$242K	–	418
2019 Q1	$242K	Buy	+1,318	New	+$243K	0.14%	191

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Neo Ivy Capital Management's VRTX Position: Q4 2025 in Review

Neo Ivy Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 7,256 shares — an estimated $2.84M sold.

Neo Ivy Capital Management first reported a position in VRTX in Q1 2019 and held it in 11 quarters. The position peaked at $2.84M in Q3 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Neo Ivy Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Neo Ivy Capital Management sold 7,256 Vertex Pharmaceuticals shares in Q4 2025, an estimated $2.84M.
Neo Ivy Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 11 quarters.
Neo Ivy Capital Management's Vertex Pharmaceuticals position peaked at $2.84M in Q3 2025.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Neo Ivy Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.